Literature DB >> 34909598

ICU admission and favipiravir.

Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Year:  2021        PMID: 34909598      PMCID: PMC8630721          DOI: 10.14744/nci.2021.60234

Source DB:  PubMed          Journal:  North Clin Istanb        ISSN: 2536-4553


× No keyword cloud information.
To the Editor, We would like to share ideas on “ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol” [1]. Guner et al. [1] concluded that “The addition of favipiravir to the national COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation”. The favipiravir is the new hope for COVID-10 outbreak containment. However, the insufficiency and unavailability are main problems in many developing countries. The decreased ICU described by Guner et al. [2] might be an effect of favipiravir use. However, it might also be the effect by other factors such as other infectious disease control process, a good supportive treatment, and seasonal fluctuation of disease incidence. Finally, a recent report also showed that an additional use of hydroxychloroquine plus favipiravir can provide a better outcome than favipiravir alone.
  2 in total

1.  Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.

Authors:  Rahmet Guner; Imran Hasanoglu; Bircan Kayaaslan; Adalet Aypak; Esragul Akinci; Hurrem Bodur; Fatma Eser; Ayse Kaya Kalem; Orhan Kucuksahin; Ihsan Ates; Aliye Bastug; Yasemin Tezer Tekce; Zeynep Bilgic; Fahriye Melis Gursoy; Hatice Nisa Akca; Seval Izdes; Deniz Erdem; Emra Asfuroglu; Habibe Hezer; Hatice Kilic; Musa Cıvak; Sibel Aydogan; Turan Buzgan
Journal:  J Infect Public Health       Date:  2020-12-29       Impact factor: 3.718

2.  ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol.

Authors:  Abdullah Emre Guner; Aral Surmeli; Kemal Kural; Habip Yilmaz; Erdogan Kocayigit; Esra Sahin; Perihan Alkan; Cemal Kazezoglu; Serdal Zelyurt; Kemal Memisoglu; Isil Maral
Journal:  North Clin Istanb       Date:  2021-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.